Portal Hypertension Complications Are Frequently the First Presentation of NAFLD in Patients Undergoing Liver Transplantation Evaluation

Digestive Diseases and Sciences

Volumn 61, Issue 7, 2016, Pages 2102-2107

  Nagpal, Sajan Jiv Singh ^a   Kabbany, Mohammad Nasser ^a   Mohamad, Bashar ^a   Lopez, Rocio ^a   Zein, Nizar N ^a   Alkhouri, Naim ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Cryptogenic cirrhosis; Liver transplantation; Nonalcoholic steatohepatitis; Portal hypertension

Indexed keywords

ADULT; ALCOHOL CONSUMPTION; ARTICLE; ASCITES; BODY MASS; BRAIN DISEASE; COMPARATIVE STUDY; DIABETES MELLITUS; END STAGE LIVER DISEASE; FEMALE; HEPATIC ENCEPHALOPATHY; HIGH RISK POPULATION; HUMAN; HYPERCHOLESTEROLEMIA; INTERNATIONAL NORMALIZED RATIO; LIVER CIRRHOSIS; LIVER GRAFT; LIVER HEMORRHAGE; MAJOR CLINICAL STUDY; MALE; MASS SCREENING; MIDDLE AGED; NONALCOHOLIC FATTY LIVER; PORTAL HYPERTENSION; PRACTICE GUIDELINE; PRIORITY JOURNAL; SURGICAL PATIENT; TERTIARY CARE CENTER; THROMBOCYTOPENIA; COMPLICATION; LIVER TRANSPLANTATION; NON-ALCOHOLIC FATTY LIVER DISEASE; RISK FACTOR;

FEMALE; HUMANS; HYPERTENSION, PORTAL; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; RISK FACTORS;

EID: 84961219067     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-016-4124-3     Document Type: Article

References (27)

1. Younossi ZM, Stepanova M, Afendy M, et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2011;9:524.e1–530.e1. (quiz e60).
2. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatol Baltim Md. 2012;55:2005–2023.
3. Wong RJ, Aguilar M, Cheung R, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology. 2015;148:547–555.
4. Holmes JA, Thompson AJ. Interferon-free combination therapies for the treatment of hepatitis C: current insights. Hepatic Med Evid Res. 2015;7:51–70.
5. Ahmed A, Wong RJ, Harrison SA. Nonalcoholic fatty liver disease review: diagnosis, treatment, and outcomes. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2015;13:2062–2070.
6. Lazo M, Hernaez R, Eberhardt MS, et al. Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988–1994. Am J Epidemiol. 2013;1:38–45.
7. Williams CD, Stengel J, Asike MI, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2011;140:124–131.
8. Yilmaz Y, Younossi ZM. Obesity-associated nonalcoholic fatty liver disease. Clin Liver Dis. 2014;18:19–31.
9. Gerber LH, Weinstein A, Pawloski L. Role of exercise in optimizing the functional status of patients with nonalcoholic fatty liver disease. Clin Liver Dis. 2014;18:113–127.
10. Barrera F, George J. The role of diet and nutritional intervention for the management of patients with NAFLD. Clin Liver Dis. 2014;18:91–112.
11. Tham KY, Ong JJ, Tan DK, How KY. How much do diabetic patients know about diabetes mellitus and its complications? Ann Acad Med Singap. 2004;33:503–509.
12. Rhodes KS, Bookstein LC, Aaronson LS, Mercer NM, Orringer CE. Intensive nutrition counseling enhances outcomes of National Cholesterol Education Program dietary therapy. J Am Diet Assoc. 1996;96:1003–1010. (quiz 1011–1012).
13. Masuoka HC, Chalasani N. Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individuals. Ann NY Acad Sci. 2013;1281:106–122.
14. Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol. 2013;10:330–344.
15. Gupte P, Amarapurkar D, Agal S, et al. Non-alcoholic steatohepatitis in type 2 diabetes mellitus. J Gastroenterol Hepatol. 2004;1:854–858.
16. Jimba S, Nakagami T, Takahashi M, et al. Prevalence of non-alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults. Diabetes Med. 2005;1:1141–1145.
17. Park S-K, Kim NH, Jung YS, et al. Risk of developing advanced colorectal neoplasia after removing high-risk adenoma detected at index colonoscopy in young patients: a KASID Study. J Gastroenterol Hepatol. 2015. doi:10.1111/jgh.13167.
18. Kwok R, Choi KC, Wong GL-H, et al. Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study. Gut. 2015. doi:10.1136/gutjnl-2015-309265.
19. Zoppini G, Fedeli U, Gennaro N, Saugo M, Targher G, Bonora E. Mortality from chronic liver diseases in diabetes. Am J Gastroenterol. 2014;109:1020–1025.
20. Scaglione S, Kliethermes S, Cao G, et al. The epidemiology of cirrhosis in the united states: a population-based study. J Clin Gastroenterol. 2015;49:690–696.
21. Wieland AC, Mettler P, McDermott MT, Crane LA, Cicutto LC, Bambha KM. Low awareness of nonalcoholic fatty liver disease among patients at high metabolic risk. J Clin Gastroenterol. 2015;49:e6–e10.
22. Greene J, Hibbard JH. Why does patient activation matter? An examination of the relationships between patient activation and health-related outcomes. J Gen Intern Med. 2012;27:520–526.
23. Keating SE, Hackett DA, George J, Johnson NA. Exercise and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol. 2012;57:157–166.
24. Huang W-K, Chang JW-C, See L-C, et al. Higher rate of colorectal cancer among patients with pyogenic liver abscess with Klebsiella pneumoniae than those without: an 11-year follow-up study. Colorectal Dis Off J Assoc Coloproctology G B Irel. 2012;14:e794–e801.
25. Ueno T, Sugawara H, Sujaku K, et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol. 1997;27:103–107.
26. Neuschwander-Tetri BA, Loomba R, Sanyal AJ, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet Lond Engl. 2015;14:956–965.
27. Bergqvist C-J, Skoien R, Horsfall L, Clouston AD, Jonsson JR, Powell EE. Awareness and opinions of non-alcoholic fatty liver disease by hospital specialists. Intern Med J. 2013;43:247–253.